GWave

Key People

• General Guy Zur - Co-Founder, CEO
• Br. General Bentzi Gruber (res) - Co-Founder, Chairman
• Dr. Gerry Vaintrub - Co-Founder, CTO
• Taire Rubin - Co-Founder, VP of Business Development
• Maor Zur - COO

Assessment

Team

Aspect: First-time 10+ yrs
Summary: The leadership team comprises individuals with extensive experience in military and technological fields, including a Major General and a PhD in physics and electronics.

The leadership's background in military and technology sectors provides a strong foundation for developing and commercializing advanced medical devices.

Clinical Need

Aspect: Very Strong
Summary: GWave addresses a significant need for non-invasive, continuous glucose monitoring, offering a painless alternative to traditional methods.

With millions affected by diabetes globally, a non-invasive monitoring solution could greatly enhance patient compliance and health outcomes.

Competition

Aspect: Very crowded + Strategics
Summary: The glucose monitoring market is highly competitive, with established players like Dexcom and Abbott.

Competing against well-established firms with extensive resources requires a compelling value proposition and strategic partnerships.

Technical Challenge

Aspect: Complex
Summary: Developing accurate non-invasive glucose monitoring using RF technology involves significant technical hurdles.

The complexity of measuring blood glucose non-invasively necessitates rigorous testing and validation to meet medical standards.

Patent

Aspect: Strong
Summary: HAGAR has secured patents for its RF-based glucose monitoring technology.

Patents provide a barrier to entry for competitors and can be leveraged in strategic partnerships or licensing agreements.

Financing

Aspect: Medium
Summary: The company has raised $25 million to date, including a $5 million Series C round in August 2023.

Bringing a medical device to market involves significant costs, including manufacturing, marketing, and regulatory compliance.

Regulatory

Aspect: Pivotal Trial
Summary: GWave has received FDA Breakthrough Device Designation and is conducting clinical trials.

The Breakthrough Device Designation facilitates the regulatory process, but successful completion of pivotal trials is essential for market entry.

Opportunity Rollup

Odds of Success

3.5

Peak Market Share

4.75

Segment CAGR

9.5%

Market Segment

Glucose Monitoring

Market Sub Segment

Non-Invasive Continuous Glucose Monitoring

Key Takeaway

GWave's non-invasive glucose monitoring technology addresses a significant clinical need, but faces challenges in a competitive market and achieving regulatory approval.